CNBG invests further RMB 2 billion in Jilin High-Tech Zone facilities, GBI

Release Date: 2009-08-25

China National Biotech Group (CNBG) has started construction on additional manufacturing bases in Jilin High-Tech Development Zone with a total investment of RMB 2 billion, Jilin Daily reported August 25.

Since moving to the development zone in 2007, CNBG has finished building two manufacturing facilities for drug packing material, and a monoclonal antibody factory which will soon be on-line. The company plans to establish eight more facilities, including a research and development center, an animal laboratory, and a manufacturing factory.

CNBG is one of the largest manufacturers in China for vaccines and blood products. The new production base is expected to generate RMB 5 billion in annual sales for the company.
Type: NORMAL
Company: GBI
Country: China
Url: http://www.gbipharma.com/cpbheadline.asp?newsid=2010480
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.